CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the commercialization and development of Abecma ...

Bristol Myers Squibb (BMS) plans to buy out its partner in developing the blockbuster multiple myeloma drug Abecma ® (idecabtagene vicleucel), by agreeing to acquire 2seventy bio for ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of an asset purchase agreement (“APA”) by Novo Nordisk. Under the terms of the APA ...

Bristol Myers Squibb (NYSE:BMY) will commence a tender offer to acquire all outstanding shares of 2seventy bio at a price of $5.00 a share.The deal represents an 88% premium to the closing price ...

2seventy bio, spun off from bluebird bio in 11/2021, now has a three-year track record as an independent company in cell therapies. Small biotechs like 2seventy bio face significant challenges in ...

Bluebird bio and 2seventy bio are struggling as small biotechs in the challenging field of cell therapies. Bluebird has a longer history as a public company and has established itself as a gene ...

2seventy bio, Inc. (NASDAQ:TSVT) just released its quarterly report and things are looking bullish. 2seventy bio beat expectations with revenues of US$13m arriving 8.6% ahead of forecasts.

Sept 12 (Reuters) - 2seventy bio (TSVT.O), opens new tab said on Tuesday it plans to lay off about 40% of its workforce to lower costs and focus on the biotech firm's cancer cell therapy Abecma ...

2seventy bio, Inc. (TSVT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...

Understand the cash flow statement for 2seventy bio, Inc. (TSVT), learn where the money comes from and how the company spends it.